Compound Radar

Bausch Health Companies Inc. (BHC) Stock Analysis

Price $6.43
Market cap $2.40B
Next earnings Oct 28, 2026
Entry status Wait

Last updated Sep 8, 2026

Health Check

Last analyzed Sep 7, 2026

45
45/100 Speculative
  • Financial Health 20
  • Profitability 75
  • Business Quality 75
  • Balance Sheet 40
  • Cash Flow 80

Why this rating?

Health 45/100 — Speculative

Strongest Cash Flow 80/100
Softest Financial Health 20/100
Wait

Entry timing is weak right now. Quality may be fine; the setup is not.

Company overview

Bausch Health Companies Inc. (BHC) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector. Compound Radar rates Bausch Health Companies Inc. 45/100 (Speculative) due to high business quality, steady revenue growth, and elevated leverage.

Investment profile

  • Quality High
  • Growth Moderate
  • Balance Sheet Stretched
  • Valuation Attractive

Financial highlights

Valuation

  • Forward P/E 1.53
  • PEG 0.01
  • EV/Revenue 2.06

Profitability

  • Revenue Growth 12.7%
  • Gross Margin 71.8%
  • Operating Margin 27.2%
  • Net Margin -10.1%

Financial strength

  • Cash $1.82B
  • Debt $20.78B
  • Net Cash $-18.95B
  • Free Cash Flow $993.00M
  • Current Ratio 1.44

Similar companies

Peers in Drug Manufacturers - Specialty & Generic, ranked by Financial Health.

Company Ticker
Price Current price

Latest quoted price for the name. Helps anchor the setup in today’s market level.

Health Entry

View all in Drug Manufacturers - Specialty & Generic →

FAQ

How Compound Radar scores and tracks Bausch Health Companies Inc. (BHC).

View Methodology & FAQ →